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Introduction
More than a third of acute ischaemic stroke (AIS) patients present with increased plasma glucose on hospital admission (1, 2) . Hyperglycaemia after AIS has been acknowledged as an independent predictor of poor outcome for more than 20 years (3), and more recently several observational studies suggested that increased plasma glucose on presentation is also an independent predictor for symptomatic intracerebral haemorrhage (SICH) and unfavourable clinical outcomes in AIS patients treated with intravenous thrombolysis (IVT) (4-7).
Interestingly, this association of hyperglycaemia with poor clinical outcomes has also been reported in patients with successful recanalization following IVT (8) .
However, when stratified by the history of diabetes mellitus (DM) data from observational studies on the association of hyperglycaemia with IVT outcomes yields contradictory findings. In the Canadian Alteplase for Stroke Effectiveness Study (CASES) admission hyperglycaemia (>144 mg/dl) was independently associated with poor outcomes following IVT administration in both diabetic and non-diabetic patients (9) , while in the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR) admission hyperglycaemia was only associated with a higher risk of SICH and mortality in patients without a history of diabetes mellitus, but not in diabetic patients (10) .
In view of these discrepant findings we sought to assess the association of hyperglycaemia with early outcomes of AIS patients treated with IVT, stratified by the history of DM, using propensity score matched (PSM) data from the SITS-ISTR registry.
Methods
We analyzed prospectively collected data from the SITS-ISTR registry from participating centers treating AIS patients with IVT using the IVT register platform, as previously described (11) . We included all IVT-treated AIS patients registered in the SITS-ISTR standard dataset between January 2010 and December 2017 if they had available data regarding: 1. the history of diabetes mellitus, 2. baseline plasma glucose values, 3 . disability prior to stroke onset [modified Rankin Scale (mRS) scores more than 1], 4. three-month functional outcome assessment using the mRS-score. Patients who have had endovascular treatment, alone or following administration of tissue plasminongen activator (tPA), were excluded from the present analysis. We also excluded patients enrolled in the SITS-ISTR register before January 2010, since data of these patients have been included in a previous studies investigating the association of admission hyperglycaemia with outcomes in AIS patients treated with IVT (10).
The primary safety outcome was the difference in SICH rates according to the SITS-MOST definition (local or remote parenchymal haemorrhage type 2 on 22-36 hours post-IVT imaging scans combined with NIHSS-score increase ≥4 points or leading to death within 24 hours) (12) , while the primary efficacy outcome was the difference in functional independence (FI) rates at 3 months (defined as mRS scores 0-2) between patients with and without hyperglycaemia on hospital admission. Secondary outcome events of interest included: 1. mortality rates at 3 months, 2. favourable functional outcome (FFO) rates at 3 months (defined as mRS scores of 0 or 1), 3. SICH rates according to the ECASS II definition (any intracranial bleed with ≥4 points worsening on the NIHSS score) (13), 4 . rates of any parenchymal haemorrhage (PH), 5. the distribution of the 3-month mRS scores (functional improvement) between patients with and without hyperglycaemia on hospital admission. All outcomes were evaluated separately for diabetic and non-diabetic patients, and all analyses were performed in both the unmatched and PSM populations.
Statistical analyses
After dichotomization according to the history of diabetes mellitus and the presence of admission hyperglycaemia (≥144 mg/dl) prior to tissue plasminogen activator (tPA) bolus (14), patients in the active group (presence of admission hyperglycaemia) were matched to control group patients (absence of admission hyperglycaemia) using a structured, iterative propensity score model with the primary objective to maximize the balance in the distribution of possible confounders between the two aforementioned groups. The PSM was performed separately for diabetic and non-diabetic patients. In the PSM algorithm we included all baseline characteristics except for the history of diabetes mellitus and admission hyperglycaemia. The corresponding propensity score of the admission hyperglycaemia variable was then calculated for each subject and a nearest neighbor matching algorithm was then used to match patients with admission hyperglycaemia to patients in the control group (patients without admission hyperglycaemia) on a 1:1 ratio (with no replacement) within 0.2*SD of the logit of the propensity score. The process of PSM has been described in detail in similar analyses of SITS registry (15). To determine whether PSM achieved balance in all potential confounders, we compared all baseline characteristics of patients with admission hyperglycaemia to their PSM counterparts.
Statistical comparisons were performed between the aforementioned PSM groups using the χ2-test (or the Fisher's exact test) and the unpaired t-test (or Mann-Whitney U-test), where appropriate. The distributions of the mRS-scores at three months between the PSM groups was compared using the Cochran Mantel-Haenszel test. The associations of admission hyperglycaemia and diabetes mellitus history with the outcomes of interest were also evaluated using univariable and multivariable binary logistic or ordinal logistic regression models. In univariable models of all baseline characteristics a threshold of p<0.1 was used to identify candidate variables for inclusion in the multivariate regression models that tested statistical significance hypothesis at a significance level of 0.05.
Out of a total 109,324 consecutive AIS patients treated with IVT between January 1, 2010 and December 30, 2017 we identified 54,206 eligible patients (Figure 1 ). In the unmatched cohort, non-diabetic patients with admission hyperglycaemia were older (p<0.001), more likely to be female (p<0.001), with greater neurological severity on admission (p<0.001), a higher prevalence of hypertension (p<0.001), hyperlipidemia (p=0.012), atrial fibrillation (p<0.001) and congestive heart failure (p<0.001), a lower prevalence of current smoking (p<0.001) and previous stroke (p<0.001), higher rates of disability prior to the index event (p=0.006), higher systolic blood pressure on admission and longer onset-to-treatment times (p<0.001) compared to non-diabetic patients without admission hyperglycaemia. Non-diabetic patients with admission hyperglycaemia had lower rates of 3- In the unmatched cohort of diabetic patients, individuals with admission hyperglycaemia were younger (p<0.001), with a lower prevalence of hyperlipidaemia (p<0.001) and higher systolic and diastolic blood pressure on admission (p<0.001) compared to diabetic patients without admission hyperglycaemia (eTable 1, appendix). Diabetic patients with admission hyperglycaemia had lower rates of 3-month FFO (32.7% vs. 37.7%, p<0.001) and FI (46.3% vs. 50.6%, p<0.001), higher rates of any PH (7.5% vs. 6.1%, p=0.008) and SICH according to the ECASS II definition (7.3% vs. 6.2%, p=0.039), higher 3-month mortality rates (2.6% vs. 2.1%, p<0.001) and higher mRS scores at 3-months [3 (1-6) vs. 2 (1-5), p<0.001].
There was no difference in the SITS-MOST SICH rates (2.8% vs. 2.3%, p=0.130) between the two groups (diabetic patients with and without admission hyperglycaemia). PSM in non-diabetic patients resulted in two groups of 6,159 patients each (Figure 1 ), balanced for all baseline characteristics ( (Figure 2A ). We detected no difference in the rates of any PH (5.1% vs. 4.6%, p=0.176) and SICH between the two groups according to SITS MOST (1.7% vs. 1.8%, p=0.563) and ECASS II definitions (5.0% vs. 4.6%, p=0.307).
Likewise, PSM in diabetic patients resulted in two groups of 3,286 patients each (Figure 1 ), balanced for all baseline characteristics ( Figure 2B ). There was no difference in the rates of any PH (6.4% vs. 6.1%, p=0.551) and SICH according to SITS-MOST (2.2% vs. 2.7%, p=0.224) and ECASS II definitions (6.9% vs. 5.8%, p=0.084) between the two groups.
Both history of diabetes mellitus and admission hyperglycaemia were independently (p<0.05) associated with a lower likelihood of 3-month FFO and 3-month FI, higher risk of 3-month mortality and worse 3-month functional outcomes (shift analysis) on multivariable logistic regression analyses of the unmatched cohort after adjustment for potential confounders (Table 2 & Finally, increasing admission plasma glucose levels were linearly associated with lower odds of 3-month FI (unadjusted analyses, Figure 3A ) and of 3-month FFO (unadjusted analyses, eFigure 4, appendix) both in diabetic and non-diabetic patients. We also documented a linear relationship of increasing admission plasma glucose levels with higher likelihood of 3-month mortality both in diabetic and non-diabetic patients ( Figure 3B ). The associations of admission plasma glucose levels with outcomes of interest on multivariable logistic regression analyses of the unmatched cohort after adjustment for potential confounders are presented in eTable 7. Increasing admission plasma glucose levels were associated with higher adjusted odds of 3-month mortality, while they were negatively related to the likelihood of 3-month FFO, FI and functional improvement. No independent association of admission plasma glucose with SICH according to the SITS MOST definition was found.
Discussion
Our study showed that admission hyperglycaemia is associated with unfavourable clinical outcomes, including 3-month FFO, FI and functional improvement, in both diabetic and non-diabetic AIS patients. These associations were documented both in the unmatched cohort following adjustment for potential confounders and in the PSM cohorts of diabetics and non-diabetics AIS patients. We documented no relationship of admission hyperglycaemia with the risk of SICH in either diabetic or non-diabetic AIS patients.
Our results are in agreement with the findings of the CASES study (9) , confirming hyperglycaemia as an independent risk factor for unfavourable outcomes in AIS patients receiving IVT treatment, while they are not in accordance to the findings of the previous SITS report (10) suggesting potential disparities in the association of admission hyperglycaemia with early functional outcomes according to the history of diabetes mellitus. However, it should be noted that the difference in findings may be attributed to differences in sample sizes (16.049 AIS patients in the previous study (10) vs. 54.206 AIS patients in the current report) and statistical analysis plan (PSM vs. multivariable analyses adjusting for confounders). Despite the strong association of hyperglycaemia in AIS outcomes, also evident in cases of large vessel occlusion treated with mechanical thrombectomy (18, 19) , there is currently evidence of improved outcomes in AIS with hyperglycaemia and tight glycaemic control in the acute phase, in patients treated conservatively (20, 21) Hyperglycaemia during the acute phase of stroke may indicate patients with abnormal glucose metabolism, who are known to have an increased risk for adverse cardiovascular outcomes (27). Hyperglycaemia is also known to enhance glucose and energy delivery to the ischaemic tissue at the cost of exacerbation of cell injury through multiple mechanisms, including lactic acidosis and oxidative stress (28). Experimental models suggest that hyperglycaemia following ischaemia results in blood-brain barrier dysfunction through an increase in oxidative stress and matrix metalloproteinase-9 activity (29). Post-ischaemic hyperglycaemia has also been associated with exacerbation of ischaemic neuronal damage mediated by transporter signalling (30, 31), in both normal animals and animals with metabolic syndrome (32), and with ineffective collateral circulation due to impaired cerebrovascular reactivity (33). Interestingly, in a small cohort increased blood glucose was associated with greater acute-subacute lactate production and reduced salvage of brain tissue only in AIS patients with perfusion-diffusion mismatch, and not in AIS patients without evidence of viable penumbra on neuroimaging (34).
Baseline plasma glucose prior to IVT administration has been incorporated in the available prediction scores for post-IVT SICH, namely the SITS SICH score (35), the haemorrhage after thrombolysis (HAT) score (36), the SEDAN score (37) and the STARTING-SICH score (38) . However, in a retrospective cohort study of 1,112 IVT-treated consecutive AIS patients not only baseline plasma glucose, but also glycated hemoglobin (HbA1c) was highlighted as an important predictor of SICH risk following IVT administration, suggesting that the association between increased plasma glucose and sICH risk may be a consequence of long-term vascular injury attributed to diabetes mellitus rather than the sole result of acute hyperglycaemia (39).
Compared to previous reports our study included significantly higher numbers of both diabetic and non-diabetic patients, incorporating also AIS patients more than 80 years of age and with IVT administration beyond 3 hours. Additionally, we are the first to provide PSM analyses on the association of baseline plasma glucose with outcomes separately for diabetic and non-diabetic patients. Despite these strengths, some limitations of the current report also need to be acknowledged. First, selection and reporting biases cannot be excluded in this retrospective analysis of prospectively collected data from a multinational registry with selfreported safety and effectiveness outcomes and no central adjudication of imaging and clinical outcomes. It should also be noted that the history of diabetes mellitus was recorded according to the relevant information provided in the registry, while glycated hemoglobin (HbA1c) values were not available. Therefore, the possibility that some patients with either undiagnosed diabetes or with unrecorded (in the charts) history of diabetes being falsely allocated to the group of non-diabetic subjects cannot be excluded. Secondly, although PSM groups were balanced for all available baseline characteristics potential imbalances in unmeasured confounders cannot be excluded. More specifically, in diabetic patients we were not able to assess potential drug-class effects of antidiabetic medications on stroke outcomes following IVT (40) (41) (42) . Additionally, information on antidiabetic treatment duration, adherence and longterm control of diabetes were not available. Likewise, information on the causes of death events is unavailable and thus the relative risk of SICH-related mortality between the two groups cannot be assessed. However, it should be noted that cerebral edema represents a substantial cause of 3-month mortality in SITS registry ranging from 18% to 65% according to cerebral edema type (43) . Third, it should be noted that the cut-off value of 144 mg/dl (8 mmol/L) in admission glucose for the definition of hyperglycemia was used for comparability to other studies (3, 8, 9, 14) . Thus, the optimal threshold for the definition of clinically relevant hypeglycemia in AIS patients eligible for IVT treatment remains unknown. Finally, missing three month follow-up in a third of total patients and unavailable outcomes of interest in nearly half of the whole patient population included in the present registry (Figure 1 ) may have introduced additional bias on the reported associations.
In conclusion, our findings indicate that admission hyperglycaemia is associated with unfavourable clinical outcomes in both diabetic and non-diabetic tPA-treated AIS patients in adjusted and PSM analyses. We found no significant increase in the risk of SICH in hyperglycaemic AIS patients treated with IVT. Future randomized-controlled clinical trials on the potential utility of moderate glycaemic control in the population of AIS patients treated with IVT that present with hyperglycaemia before tPA-bolus appear to be warranted.
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